A5329: Interferon –Free Therapy for Chronic Hepatitis C Virus Genotype 1 infection in persons with HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy: A5334s Pharmacokinetic Substudy

Study Location:

Baltimore

Topic:

Hepatitis and HIV

Clinicaltrials.gov Link:

https://clinicaltrials.gov/ct2/show/NCT02194998?term=a5329&rank=1

IRB#:

Pro00010596

Coordinator:

Anna Wimpelberg (Washington)

​Ilene Wiggins, RN (Baltimore)
 

Enrollment:

Closed

Trial Period:

Ongoing

A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C medications.  New “direct acting antiviral” drugs (DAAs) ABT-450/r/ABT-267 plus ABT-333 will be tested as part of a drug regimen that does not contain the drug interferon for either 24 or 12 weeks of treatment. 

  • HIV and Hepatitis C co-infected people 18 to 70 years old
  • HIV viral load less than 50 copies
  • Currently on one of the following HIV regimens:  
    • raltegravir or darunavir/ritonavir  AND tenofovir plus FTC or 3TC
  • No history of resistance or failure of anti-HIV therapy
  • CD4 count greater than 200
  • No prior HCV treatment
  • HCV viral load greater than 10,000
  • HCV genotype 1

Anna Wimpelberg (Washington)
202-797-3589
awimpelberg@whitman-walker.org


​Ilene Wiggins, RN (Baltimore)
410-614-2766
iwiggin1@jhmi.edu

Categories

Location
Topic

Clinical Trials

A5349: Rifapentine-containing treatment shortening regimens...

The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a...

Read More

NWCS 414, Evaluation of a Serum Biosignature for Identifying...

We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More

The Pharmacokinetics, Safety and Acceptability of New...

PK, safety and acceptability data and practical guidance on the optimal dosing of new more child-friendly formulations of...

Read More

P1060:  Phase II, parallel, randomized, clinical trials...

A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a single dose to her infant has been...

Read More